Results 231 to 240 of about 14,544 (270)

Inhibition kinetics of human kidney aldose and aldehyde reductases by aldose reductase inhibitors

Biochemical Pharmacology, 1990
Kinetic patterns of inhibition of homogenous human kidney aldose reductase (AR, EC 1.1.1.21) and aldehyde reductase II (AR II, EC 1.1.1.19) by statil, ICI 105552 [1-(3,4-dichlorobenzyl)-3-methyl-1,2-dihydro-2-oxoquinol-4-yl acetic acid], tolrestat, alrestatin, chromone carboxylic acid (CCA), quercetin, phenobarbital and sorbinil were studied.
A, Bhatnagar, S Q, Liu, B, Das, N H, Ansari, S K, Srivastava   +4 more
openaire   +2 more sources

Thienocinnolinone Alkanoic Acid Derivatives as Aldose Reductase Inhibitors

Medicinal Chemistry, 2006
A new series of 8-halogen-4,4a,5,6-tetrahydrothieno[2,3-h]cinnolinone-N2-alkanoic acids was prepared and tested for aldose reductase (ALR2) inhibitory activities. These compounds showed significant inhibitory activity against bovine lens ALR2, with the best compound 2e showing an IC(50) value of 31.4 microM.
Pau, A, Asproni, B., Murineddu, G., Boatto, G., Grella, G. E., Rakowitz, D., COSTANTINO, Luca, Pinna, G. A.   +7 more
openaire   +4 more sources

Aldose reductase inhibitors as pathobiochemical probes

Journal of Diabetes and its Complications, 1992
In tissues susceptible to damage from chronic diabetes, excess glucose is metabolized by aldose reductase (AR) to sorbitol. Originally, AR-catalyzed sorbitol formation (and accumulation) was found in the diabetic lens; the cataractogenicity of this process was proven by preventing cataract formation with an AR inhibitor (ARI).
openaire   +2 more sources

Inhibitors of Aldose Reductase

1992
Abstract Aldose reductase (AR) inhibitors are designed to interfere with the initiation and early development of secondary complications of chronic diabetes mellitus. The concept was deduced from the insight that, in diabetic tissues with insulin-independent glucose uptake, excess glucose is metabolized via the polyol (sorbitol) pathway.
openaire   +1 more source

Recent Clinical Experience With Aldose Reductase Inhibitors

Diabetic Medicine, 1992
Since 1981 a number of aldose reductase inhibitors (ARIs) have been extensively investigated in clinical trials for the treatment or prevention of diabetic complications. In general, the results from these trials have varied from no effect to improvement. In part, the inconclusive results are due to differences in the study designs.
openaire   +3 more sources

The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Ca-A Cancer Journal for Clinicians, 2022
Sharon Elad, Noam Yarom, Yehuda Zadik
exaly  

The Pharmacology of Aldose Reductase Inhibitors

Annual Review of Pharmacology and Toxicology, 1985
P F, Kador, W G, Robison, J H, Kinoshita
openaire   +3 more sources

Benzothiazole aldose reductase inhibitors

Drugs of the Future, 1998
null Ashizawa, N., null Aotsuka, T.
openaire   +1 more source

Aldose reductase inhibitors and diabetic complications

The American Journal of Medicine, 1987
P, Raskin, J, Rosenstock
openaire   +2 more sources

Medicinal chemistry of aldose reductase inhibitors

Medicinal Research Reviews, 1988
E R, Larson, C A, Lipinski, R, Sarges
openaire   +2 more sources